Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results
Date:2/24/2011

opean approval in the first half of 2011.  Additionally, our work will accelerate in 2011 toward expanding the use of C1 esterase inhibitor into other complement-mediated diseases."

The Company is reporting both GAAP net income (loss) and non-GAAP adjusted results for the three and twelve months ended December 31, 2010 and 2009.  Non-GAAP adjusted net income is GAAP net income excluding (1) non-cash interest expense, (2) amortization related intangible assets acquired, and step up in inventory related to purchase accounting, (3) stock compensation expenses, and (4) certain non-recurring events such as the goodwill write off, impairment loss and gain on extinguishment of repurchased bonds.  A reconciliation between GAAP and non-GAAP adjusted net income is provided in the Selected Financial Information - Reconciliation of GAAP Net Income (loss) to non-GAAP adjusted Net Income table included with this release.

The Company believes it is important to share these non-GAAP financial measures with shareholders as they better represent the ongoing economics of the business and reflect how we manage the business.  Accordingly, management believes investors' understanding of the Company's financial performance is enhanced as a result of our disclosing these non-GAAP financial measures. Non-GAAP adjusted net income should not be viewed in isolation, or as a substitute for or superior to reported GAAP net income (loss). ViroPharma's definition of non-GAAP financial measures may differ from others.

Non-GAAP adjusted net income in the three and twelve months ended December 31, 2010 was $45.6 million and $156.9 million, respectively, compared to $20.8 million and $83.6 million, respectively, for the same periods in 2009.  The increase in adjusted net income for both periods is primarily due to the net effect of the Cinryze launch and lower research and development expenses, partly offset by increased cost of sales due to the increase
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 Whitehouse Laboratories is ... term partnership with PTI Inspection Systems that ... state of the art leak testing method development and ... instruments currently available. As part of this agreement, Whitehouse ... Voltage Leak Detection Instrument developed and manufactured by ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Green & ... in Series B funding and secured Otter Capital as ... capital will accelerate commercialization of GGI’s Agriplier™ technology, building ... types. , “Since our first meeting, we have ... the biological product space,” said Alan Sobba, President and ...
(Date:8/27/2014)... August 27, 2014 In 2013, ... Lawrence Livermore National Security LLC (LLNS), ... and deliver a state-of-the-art laser system for the ... Beamlines), under construction in the Czech Republic. , ... laser system, called the " High repetition-rate Advanced ...
(Date:8/27/2014)... 27, 2014   MSC , a healthcare performance ... announced the appointment of Mary Beth Loesch ... years of experience preparing companies for rapid growth and ... Vice President of Corporate Development and Healthcare. In that ... , as well as corporate strategy and marketing. Previously, ...
Breaking Biology Technology:Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2
... Inc. (OTCBB: MDXG), an integrated developer, manufacturer and ... processed from human amniotic membrane, announced today that ... convertible notes and warrants has been fully subscribed. ... October 15, 2011, the Company received $5,000,000 in ...
... many Americans are resolving to address financial issues or lose ... are looking to find answers to an important question – ... which was commissioned by Identigene, the largest direct-to-consumer DNA paternity ... the only paternity test available at the drug store, reveals ...
... Cord Blood America, Inc . ( http://www.cordblood-america.com ) ... blood stem cell preservation company focused on bringing ... and internationally, is pleased to announce it has signed an ... laboratory for the National Children,s Leukemia Foundation (NCLF), New York. ...
Cached Biology Technology:MiMedx Group Completes $5,000,000 Private Placement 2MiMedx Group Completes $5,000,000 Private Placement 3Survey Reveals Paternity Questions Loom for More Than One in 10 Americans 2Survey Reveals Paternity Questions Loom for More Than One in 10 Americans 3Cord Blood America Announces Exclusive Agreement With National Children's Leukemia Foundation to Store Stem Cells 2
(Date:8/29/2014)... A leading U.S. Ebola researcher from the University of Texas ... a blend of three monoclonal antibodies can completely protect monkeys ... days after infection, at a time when the disease is ... written an editorial for Nature discussing advances in ... Marburg virus are among the most deadly of pathogens, with ...
(Date:8/29/2014)... researchers explored the type and number of connections in ... plays on robustness in a study published in ... found that the assortativity signature contributes to a network,s ... that varying the out-out assortativity of TFN models has ... the other three types of assortativity," said Dov A. ...
(Date:8/29/2014)... news release is available in German . ... chemical signals between organisms is considered the oldest form ... interactions between conspecifics, for example, the sexual attraction between ... social responses and to coordinate reproductive behavior in males ... the University of the Algarve in Faro, Portugal, and ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Assortativity signatures of transcription factor networks contribute to robustness 2Ready for mating at the right time 2Ready for mating at the right time 3
... JUPITER, FL -- Scripps Florida scientists have been awarded ... part of the National Institutes of Health, to study ... be effective in controlling pain without the unwanted side ... and Vicoden. Laura Bohn, an associate professor ...
... Adding prebiotic ingredients to infant formula helps colonize ... bacteria, and probiotics enhance immunity in formula-fed infants, two ... bacteria that live in a baby,s intestine are all-important ... off infections," said Kelly Tappenden, a U of I ...
... quickly identifying them can be crucial to stopping an ... hours and days. But not for much longer. ... electrical engineering at the University of Tennessee, Knoxville, and ... at the UT Institute of Agriculture Center for Wildlife ...
Cached Biology News:Scripps Florida scientists awarded $3 million to develop new, more effective pain treatments 2New infant formula ingredients boost babies' immunity by feeding their gut bacteria 2University of Tennessee researchers invent device to rapidly detect infectious disease 2
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
Request Info...
... are available in two product models - the ... models is that the 6000AT+ includes a membrane ... aerosol for improved detection limits and reduced oxides. ... range of elements by 10-40 times. Note that ...
... available in two product models - the 5000AT+ ... is that the 6000AT+ includes a membrane desolvation ... for improved detection limits and reduced oxides. The ... of elements by 10-40 times. Note that with ...
Biology Products: